Mercy Hospital Janesville | |
1000 Mineral Point Ave, Janesville, WI 53548-2940 | |
(608) 756-6000 | |
Not Available |
Full Name | Mercy Hospital Janesville |
---|---|
Type | Facility |
Speciality | General Acute Care Hospital |
Location | 1000 Mineral Point Ave, Janesville, Wisconsin |
Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1093768962 | NPI | - | NPPES |
11011426 | Medicaid | WI | |
43009200 | Medicaid | WI | |
11011400 | Medicaid | WI | |
43171321 | Medicaid | WI |
Mailing Address | Practice Location Address |
---|---|
Mercy Hospital Janesville 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 756-6000 | Mercy Hospital Janesville 1000 Mineral Point Ave, Janesville, WI 53548-2940 Ph: (608) 756-6000 |
News Archive
Glasgow-based bio-engineering group HCi Viocare - the company behind the Smart Insole invention that monitors diabetic feet – today announced that it is extending its push into healthcare by developing new adaptations of their innovative technology.
Scientists at Royal Holloway, University of London have reported encouraging results in a new gene-based therapy for Duchenne Muscular dystrophy (DMD) which at present has no known cure and affects one in 3,000 young boys.
Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Open the medicine cabinet of a senior and you're likely to find scores of pill bottles. Physicians are often unaware of all the medications a patient is taking, which can result in unnecessary additional prescriptions, non-prescription medications and potential drug-drug interactions that cause unexpected adverse effects.
Nuvera Biosciences, a molecular diagnostics company that develops gene-based diagnostic assays for personalized medicine in cancer, announced the results of a blinded validation study on its breast cancer assay for taxane chemotherapy response.
› Verified 5 days ago